导读： 根据2024年财报显示，国内上市仪器企业净利润为正的有38家，净利润为负的有7家，增幅最高 为455.96%，最低为-760.56%。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2 0 2 4 年，在国际环境复杂多变、关税战频发的背景下，叠加人工智能、物联网及大数据等前 沿技术迅猛发展的时代浪潮，国内 相关企业 正迎来 变革和 转型的关键之年 ，机遇与挑战并 存 。面对外部压力与技术迭代的双重驱动，企业积极在技术创新、产品升级和市场布局等方面 寻 求 突 破 。 特 别 是 在 科 学 仪 器 领 域 ， 越 来 越 多 的 企 业 加 快 融 合 新 兴 技 术 ， 推 动 产 品 向 智 能 化、网络化、集成化方向升级， 以 提升 自身的 核心竞争力。 近 日 ， 仪器信息网以国内 4 5 家 上 市 仪 器 企 业 为 研 究 对 象 ， 根 据 其 公 布 的 财 报 数 据 ， 列 出 2 0 2 4 年归属于上市公司股东的净利润 TOP4 5 榜单 ，并对其进行了相关分析，请大家查阅。 | 最新 排名 | 企业名 ...

Core Viewpoint - Central to the article is the announcement of multiple government procurement intentions by Central South University, detailing 28 items of laboratory equipment with a total budget of 128 million yuan, scheduled for procurement between April and December 2025 [1][2]. Summary by Relevant Sections Procurement Overview - Central South University has outlined procurement intentions for various scientific instruments, with a total budget of 128 million yuan [1][2]. - The procurement includes advanced equipment such as ultra-high temperature synchronous thermal analyzers, multi-field coupled low-field nuclear magnetic resonance imaging instruments, X-ray fluorescence spectrometers, and quantum efficiency testing instruments [2]. Specific Equipment Details - **Ultra-high Temperature Synchronous Thermal Analyzer**: - Quantity: 1 unit - Purpose: To study thermal changes and mass changes of materials under high-temperature conditions [4]. - **Multi-field Coupled Low-field Nuclear Magnetic Resonance Imaging Instrument**: - Quantity: 1 unit - Purpose: To analyze the microstructure and fluid information of porous media samples under various conditions [4][10]. - **X-ray Fluorescence Spectrometer**: - Quantity: 1 unit - Purpose: For qualitative and quantitative analysis of materials, covering elements from Be to U [5][9]. - **Quantum Efficiency Testing Instrument**: - Quantity: 1 unit - Purpose: To measure the quantum efficiency of new solar cells and other materials [5]. Additional Equipment and Applications - **Scanning Electron Microscope**: - Quantity: 1 unit - Features: High-resolution imaging capabilities and various operational modes [6]. - **Laser Intelligent Processing Platform**: - Purpose: To support advanced manufacturing education and practical training for students [6]. - **Three-dimensional X-ray Imaging System**: - Purpose: To enhance scanning capabilities for larger samples [9]. Budget and Timeline - The total budget for the procurement is set at 128 million yuan, with the procurement process expected to take place from April to December 2025 [1][2].

Core Viewpoint - The article discusses the naming conventions of analytical instruments as per the standard GB/T12519-2021, emphasizing the importance of adhering to established naming principles to avoid confusion in the industry [1][2]. Group 1: Naming Principles - The naming of analytical instruments is guided by specific principles that consider the measurement method and the object being measured [2]. - Instruments that measure a single substance (excluding gases) and assign values are typically referred to as "meters," such as pH meters and salinity meters [2]. - Instruments designed to measure gases are generally called "analyzers," for example, carbon monoxide analyzers and carbon dioxide analyzers [2]. - Instruments that analyze images to study the morphology of substances are referred to as "microscopes," such as transmission electron microscopes and scanning electron microscopes [2]. - Systems that encompass sample processing, analytical instruments, data management, and auxiliary facilities are usually called "systems," like air quality detection systems and water quality detection systems [2]. - Other analytical instruments not fitting the above categories are generally referred to as "instruments" [2]. - Safety alarm instruments that only provide sound or light warnings are typically called "alarm devices," while those with other display methods are referred to as "explosion detectors" or "detectors" [2].

Core Viewpoint - Phoenix Optical plans to invest 85 million USD (approximately 60 million RMB) to establish a wholly-owned subsidiary in Vietnam, marking a significant step in its overseas strategic layout to meet the diversified supply chain needs of international clients and further expand its global market presence [2][3]. Investment Overview - The new company, tentatively named "Phoenix Optical (Vietnam) Co., Ltd.", will have a registered capital of 85 million USD and will be located in Vinh City, Nghe An Province, Vietnam. Its main business will include the production, processing, sales, and import-export of optoelectronic products. The project is expected to be completed and put into operation by 2026, with investment funds allocated for factory renovation, equipment procurement, and working capital [4]. Strategic Significance - This investment is a key move for Phoenix Optical to extend its industrial chain and enhance its international competitiveness. The establishment of the production base in Vietnam will help the company better serve overseas clients, respond to the global supply chain diversification trend, optimize cost structure, and improve market responsiveness. The company emphasizes that its current financial condition is stable, and this investment will not adversely affect its main business or cash flow [5]. Industry Impact - Phoenix Optical's move to establish a base in Vietnam reflects the accelerating trend of Chinese optoelectronic companies "going global." With the restructuring of global supply chains, Vietnam is becoming a hotspot for manufacturing investment due to its labor cost advantages and favorable policies. This initiative may serve as a reference for peers in the industry and promote the internationalization process within the sector [6].

Core Viewpoint - The beauty industry is currently facing a significant controversy regarding the actual content of recombinant collagen, with a focus on the lack of standardized testing methods and criteria, which has led to a trust gap between brands and consumers [2]. Group 1: Industry Controversy - A beauty blogger reported that the recombinant collagen content in a popular product was only 0.0177%, significantly below the national standard of 0.1%, and failed to detect key amino acids like glycine [2]. - The controversy centers not on the technical routes or raw material sources, but on the choice of testing methods and the absence of unified standards, which has hindered the compliant development of the medical beauty industry [2]. Group 2: Regulatory Developments - Since 2022, the National Medical Products Administration (NMPA) has been releasing industry standards for recombinant collagen, including YY/T 1849-2022 and YY/T 1888-2023, to address the heterogeneity of recombinant collagen products [3]. - The introduction of mass spectrometry as a "gold standard" for quality control in recombinant collagen is expected to replace traditional methods that are susceptible to interference from other proteins [3]. Group 3: New Standards Implementation - On August 1, 2022, the NMPA implemented YY/T 1805.3-2022, which provides a high-specificity method for detecting collagen content using LC-MS/MS, addressing the limitations of traditional methods [4]. - A new standard, YY/T 1954-2025, for peptide fingerprint analysis of recombinant collagen is set to be implemented on March 1, 2026, which will enhance quality control and regulatory capabilities in the medical beauty industry [8]. Group 4: Industry Support and Collaboration - The Instrument Information Network is actively monitoring developments in cosmetic testing and promoting collaboration in the field, emphasizing the importance of advancements in testing technology and equipment [13].

导读： 在所有测试任务中，Biomni 展现出显著的性能优势：相较于基础大语言模型提升 402.3%！目前研究团队在https://biomni.stanford.edu/开放免费注册 和使用。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 2025 年 6 月 2 日，斯坦福大学 黄柯鑫、Serena Zhang、王瀚宸、屈元昊、陆荧洲 等研究人员领衔的团队，联合 Genentech、Arc Ins titute、加州大学旧金山分校及普林斯顿大学等多个顶尖研究机构，发布了一款通用生物医学 AI 智能体—— Biomni 。该智能体能够自主 完成横跨遗传学、基因组学、微生物学、药理学和临床医学等多个生物医学分支领域的复杂研究任务。 Biomni 通过将分散的科研资源整合为可操作的智能体行为单元，不仅破解了传统研究流程的碎片化瓶颈，更可能催生跨学科、高通量的自主 化科学发现引擎。 该研究以：Biomni : A General-Purpose Biomedical AI Agent 为题，发表在了预印本平台 bioRx i v。 更重要的是 ...

Core Insights - The successful installation of Asia's first CellXpress.ai in vitro model intelligent factory marks a significant milestone in the strategic collaboration between Danaher Group's Molecular Devices and the Shanghai National Engineering Research Center for Biochips [2][3]. Industry Transformation - The FDA Modernization Act 2.0, enacted in 2022, has fundamentally transformed the preclinical research landscape by recognizing non-animal testing alternatives, allowing the use of organoid models, organ-on-a-chip technologies, and AI algorithms for drug safety and efficacy assessments [3]. - A policy update from the FDA in April 2025 mandates the gradual elimination of mandatory animal testing for specific drugs, integrating organoid and organ-on-a-chip technologies with AI into the regulatory framework [3]. Technological Advancements - The CellXpress.ai platform automates the entire 3D biology process through AI-driven monitoring, cultivation, imaging, and scheduling, significantly reducing manual labor and enhancing efficiency [4]. - Key innovations of the CellXpress.ai system include: - Continuous operation 24/7, ensuring strict control over cultivation and passage schedules, thereby minimizing manual intervention [4]. - Standardized output through AI analysis, providing consistent and physiologically relevant results [4]. - Enhanced growth and expansion efficiency for various stem cell lines and organoids, optimizing screening processes [4]. Broader Implications - The deployment of the CellXpress.ai factory addresses long-standing challenges in the commercialization of organoid technology, such as operational complexity and reproducibility issues [5]. - The integration of organoid technology is expected to accelerate drug development, improving the efficiency of drug safety and efficacy evaluations in response to regulatory demands [5]. - Establishing a national standard for organoid technology is anticipated, promoting the standardized development of this field in China [5]. - The collaboration aims to enhance academic exchanges and training, contributing to the cultivation of high-quality professionals in the organoid industry [5].

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日，市发改委印发《关于开展重点领域设备购置与更新改造贷款贴息的实施方案》，进一步 加大对科技创新与研发等八大重点领域设备购置与更新改造贷款贴息的支持力度，预计获支持 的项目在贴息期内融资成本可下降超七成。 今年重点支持的领域包括：科技创新与研发、战略性新兴产业、未来产业、先进制造业和现代 服务业"两业"融合发展、新型基础设施、社会投资公共服务、文化旅游与消费场所改造升级、 农业等8个领域。这 八大领域覆盖基础研究、原创性引领性科技攻关，医药健康、集成电路、 汽车、人工智能等战略性新兴产业，生物制造、量子科技、具身智能、商业航天、智能机器人 等未来产业，数据中心、云计算、智慧交通基础设施等新基建 。 根据政策，本市将发挥政府投资引导带动作用，积极为社会投资项目降低融资成本，对符合条 件的项目给予最高不超过2.5个百分点的贴息，贷款实际利率低于2.5%的按照贴息率不超过贷 款实际利率安排。贴息期限2年。 "按商业银行中长期贷款利率、即5年期以上LPR为3.5%左右测算，预计获支持的项目在贴息 ...

Core Viewpoint - The article discusses the current status and challenges of domestic scientific research instruments in the life sciences sector, emphasizing the need to enhance the acceptance and sustainable development of these instruments to support China's technological self-reliance and strength [1][2]. Group 1: Current Situation of Domestic Instruments - A significant reliance on imported instruments exists in laboratories, with domestic instruments primarily limited to refrigerators [2]. - The number of domestic high-end instruments entering public technology platforms remains limited, highlighting a long-term dependency on imports in the scientific research instrument sector [2]. Group 2: Impact of Geopolitical Factors - The geopolitical landscape, particularly the ongoing U.S.-China tensions, is accelerating the process of domestic substitution for scientific instruments. Export controls and tariffs have increased import costs, prompting a push for self-sufficiency in critical fields such as biotechnology and semiconductors [3]. Group 3: Upcoming Initiatives - A series of programs titled "Domestic Substitution in Progress" is being launched, with the first episode scheduled for June 13, 2025. This initiative aims to gather insights from platform leaders regarding the procurement, application, and maintenance of domestic scientific instruments [3][4]. Group 4: Key Discussion Topics - The first episode will cover several key topics, including: - The current status of domestic instrument procurement and usage in public technology platforms [5]. - Challenges faced in the final stages of domestic instrument implementation [5]. - Practical experiences and solutions from platform leaders regarding domestic instruments [5]. - Recommendations from platform leaders for overcoming challenges related to domestic instruments [5]. - Strategies for creating a sustainable ecosystem for domestic instruments [5].

Core Viewpoint - Instrument manufacturers need to focus on the dual demands of "grassroots needs" and "county-level upgrades," and prepare channels and technical reserves in advance [1][32]. Policy Analysis - The policy will significantly drive the bulk procurement demand for several types of medical instruments, leading to structural growth [5]. 1. Imaging Diagnostic Equipment (Core Demand) - Policy Driver: The county medical community emphasizes the "grassroots examination, upper-level diagnosis" model, requiring basic imaging capabilities at grassroots medical institutions and high-precision diagnostic equipment at county hospitals [5]. - Procurement Focus: - Grassroots: Digital X-ray systems (DR), portable ultrasound, mobile DR for remote areas [6]. - County: 64-slice CT, 3T MRI, Digital Subtraction Angiography (DSA) [7]. - Data Support: - Anhui Province's medical community equipment update project has a budget of 120 million for CT and MRI [8]. - Sichuan Province's county medical community plans to procure 73 CT and DR units with a budget of 150 million [9]. - Heilongjiang Province plans to procure 6 MRI units with a budget of 48 million [10]. 2. Laboratory Testing Equipment (Key Support) - Policy Driver: Grassroots examinations require supporting biochemical, immunological, and microbiological testing capabilities, while county hospitals need to upgrade precision diagnostic equipment [11]. - Procurement Focus: - Grassroots: Fully automatic biochemical analyzers, urine analyzers, blood cell analyzers [12]. - County: High-resolution mass spectrometers, gene sequencers, flow cytometers [13]. - Data Support: - Henan Province's medical community equipment update project includes a budget of 330 million for fully automatic biochemical analyzers [14]. - The National Health Commission's plan requires "filling the gap in high-end medical equipment," including high-resolution mass spectrometers [15]. 3. Information Technology and Telemedicine Equipment (Core Collaboration) - Policy Driver: The medical community requires "information sharing and personnel communication," necessitating the deployment of remote consultation systems and electronic medical record sharing platforms [16]. - Procurement Focus: - Hardware: High-definition video conferencing systems, remote ECG/imaging transmission terminals, server clusters [17]. - Software: Regional medical information platforms and AI imaging analysis systems [17]. - Data Support: The National Health Commission has emphasized the application of "artificial intelligence, 5G, and big data" in county areas [18]. 4. Emergency and Transport Equipment (Emergency Assurance) - Policy Driver: The county medical community needs to strengthen emergency capabilities, covering the entire process from "initial treatment at the grassroots to rescue at county hospitals" [19]. - Procurement Focus: - Grassroots: Portable defibrillators, ventilators, monitors [19]. - County: Negative pressure ambulances, ECMO (extracorporeal membrane oxygenation), mobile ICU units [20]. - Data Support: Henan Province's medical community procurement project includes ambulances with a budget of 330 million [21]. 5. Specialized Equipment (Differentiated Demand) - Policy Driver: County hospitals need to move towards the goal of "major illnesses not leaving the county," requiring specialized equipment [23]. - Procurement Focus: - Oncology: Radiation therapy linear accelerators, intraoperative radiation therapy equipment [24]. - Cardiovascular: Cardiac CT, coronary angiography equipment, pacemaker programming instruments [25]. - Orthopedics: Digital surgical navigation systems, 3D printed implant customization equipment [26]. - Data Support: The National Health Commission's plan encourages top hospitals to procure "ultra-high field MRI, surgical robots," etc. [27]. Market Opportunities for Instrument Manufacturers - Procurement Scale Expansion: The county medical community equipment update market is expected to exceed 50 billion from 2025 to 2026 [29]. - Acceleration of Domestic Substitution: Policies encourage "domestic equipment innovation," with local manufacturers having cost advantages in CT, MRI, and biochemical analyzers [29]. - Niche Market Opportunities: High demand for small, low-cost, and easy-to-maintain equipment at the grassroots level [30]. - Information Technology Solutions: Integrated providers of "hardware + software + services" will be more competitive [31]. - Long-term Service Binding: The medical community requires equipment to be "sustainably operated and maintained," necessitating a robust after-sales service network [32].